A drug that changes how bodies process energy also changes the social life of those bodies. This is the part of the GLP-1 story that clinical trials do not measure.

GLP-1 medications — at their core, drugs for diabetes and obesity — are now taken by tens of millions of Americans. At that scale, a medical treatment becomes a cultural event. Body image norms built over decades are shifting. The fashion industry is adjusting sizing frameworks. Dating app profiles are changing. Employers are wrestling with questions of coverage equity: if weight is a health issue, does denying GLP-1 coverage discriminate against employees with obesity?

Research published this year documents the psychological complexity of the transformation. Users report not just smaller bodies but altered relationships with food — the absence of cravings they had organized their emotional lives around. This produces, depending on the individual, relief, disorientation, or grief. Behavioral health professionals are beginning to see patients who lost the weight they wanted and discovered that the hunger they were medicating was not entirely physical.

At the dating level, the dynamics are blunter. Users report changed perceptions by others and changed perceptions of others. What it means to be attracted to a body — one's own, someone else's — is not immune to pharmaceutical intervention.

None of this is a reason to oppose the drugs. It is a reason to understand that when you reshape how sixty million people experience their bodies and appetites, you have done something beyond medicine.

-- NORA WHITFIELD, New York